MedTrace Logo

Bronchial Asthma and Diabetes: Impact on Bronchial Inflammation and Exercise Capacity

NCT04448262 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2024-02-08

No results posted yet for this study

Summary

Type 2 diabetes is the most common form of diabetes and according to several studies, even lung can represent another target of the diabetic disease. Asthmatic patients often show comorbidities and obesity is one of the main.Several studies in literature suggest that patients with higher Body Mass Index (i.e. overweight and obese) have a greater risk of developing asthma compared to normal weight subjects. Considering inflammation, asthma is usually characterized by an increase of eosinophils in the airways and by a Th2 type inflammation, while a immunological type Th1 switch systemically characterizes diabetes. Even asthmatic patients, especially if diabetic, might have an increase of glucose in their airways, that could favourite or feed an inflammatory/infective state. Up to-day there are not in literature studies that have investigated the airways inflammatory pattern and the exercise capacity in relation to functional characteristics in diabetic patients affected by asthma.

Conditions

Interventions

OTHER

data collection

collection of data about bronchial and systemic inflammation, quality of life, lung function

Sponsors & Collaborators

  • Galmarini Hospital, Tradate

    collaborator UNKNOWN

  • Istituti Clinici Scientifici Maugeri SpA

    lead OTHER

Principal Investigators

  • Antonio Spanevello, Prof · ICS Maugeri

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-10
Primary Completion
2024-01-01
Completion
2024-01-12

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04448262 on ClinicalTrials.gov